These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12390940)

  • 41. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
    Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carvedilol therapy in heart failure--III.
    Lee YC
    J Am Coll Cardiol; 1995 Nov; 26(5):1400-1. PubMed ID: 7594061
    [No Abstract]   [Full Text] [Related]  

  • 43. Carvedilol and the Food and Drug Administration approval process: an introduction.
    Fisher LD; Moyé LA
    Control Clin Trials; 1999 Feb; 20(1):1-15. PubMed ID: 10027497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carvedilol in patients with chronic heart failure.
    von Olshausen K; Pop T; Berger J
    N Engl J Med; 1996 Oct; 335(17):1318-9; author reply 1319-20. PubMed ID: 8992328
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group.
    Krum H; Shusterman N; MacMahon S; Sharpe N
    J Card Fail; 1998 Dec; 4(4):281-8. PubMed ID: 9924849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials.
    Doughty RN; Rodgers A; Sharpe N; MacMahon S
    Eur Heart J; 1997 Apr; 18(4):560-5. PubMed ID: 9129883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comment on COMET: how to interpret a positive trial?
    Massie BM
    J Card Fail; 2003 Dec; 9(6):425-8. PubMed ID: 14966781
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carvedilol saves lives--new data from landmark trials prove survival benefits in heart failure and post myocardial infarction.
    Cardiovasc J S Afr; 2001; 12(2):122-3. PubMed ID: 11474697
    [No Abstract]   [Full Text] [Related]  

  • 50. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
    Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
    Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carvedilol: a countermeasure to heart failure.
    Barkman A; Pooler C
    Dimens Crit Care Nurs; 2001; 20(5):11-6. PubMed ID: 22076514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
    Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M;
    J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Major heart failure news from 2001.
    Francis D
    Heart Fail Monit; 2002; 2(4):147-8. PubMed ID: 12638556
    [No Abstract]   [Full Text] [Related]  

  • 54. [Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
    MMW Fortschr Med; 2003 Feb; 145(8):57. PubMed ID: 12661451
    [No Abstract]   [Full Text] [Related]  

  • 55. A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.
    Shepherd AM
    J Card Fail; 2003 Dec; 9(6):454-7. PubMed ID: 14966784
    [No Abstract]   [Full Text] [Related]  

  • 56. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of carvedilol on right ventricular function in chronic heart failure.
    Quaife RA; Christian PE; Gilbert EM; Datz FL; Volkman K; Bristow MR
    Am J Cardiol; 1998 Jan; 81(2):247-50. PubMed ID: 9591916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carvedilol.
    Cohn LJ
    N Engl J Med; 1999 May; 340(18):1443-4. PubMed ID: 10328713
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacist-managed carvedilol heart failure clinic.
    Darlington MR
    Am J Health Syst Pharm; 1998 Aug; 55(15):1626. PubMed ID: 9706193
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.